Full text is available at the source.
Abstract
Nanotechnology may enhance treatment options for glioblastoma multiforme (GBM) by improving drug delivery mechanisms.
- GBM is characterized by immune evasion, tumor repopulation by stem cells, and challenges with drug penetration across the blood-brain barrier.
- Nanocarrier-based systems offer benefits such as improved biosafety, sustained drug release, and enhanced solubility.
- Recent advancements in nanotechnology may help address the limitations of conventional and novel treatment modalities for GBM.
- The review provides insights into the current landscape of GBM therapeutics, including updates on drugs and patents.
- A critical evaluation of existing literature highlights both the therapeutic prospects and limitations of nanocarrier-based delivery strategies.
Simplified